Dual anti-platelet therapy with aspirin and clopidogrel reduces cardiac events in patients who have acute coronary syndromes (ACS) and in patients who have percutaneous coronary intervention (PCI). Recently, the phenomenon of "clopidogrel resistance" has received much attention because of the clinical problems of stent thrombosis and recurrent ACS. However, a precise definition of this clinical entity is lacking.